147 related articles for article (PubMed ID: 11777327)
1. Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes.
Nakamura T; Ushiyama C; Osada S; Shimada N; Ebihara I; Koide H
Ren Fail; 2001 Nov; 23(6):863-4. PubMed ID: 11777327
[No Abstract] [Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
[TBL] [Abstract][Full Text] [Related]
3. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
4. Actos (pioglitazone): a new treatment for type 2 diabetes.
Lawrence JM; Reckless JP
Hosp Med; 2001 Jul; 62(7):411-6. PubMed ID: 11480129
[TBL] [Abstract][Full Text] [Related]
5. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
King AB; Armstrong DU
Diabetes Technol Ther; 2002; 4(2):145-51. PubMed ID: 12079617
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
Nagasaka S; Abe T; Kawakami A; Kusaka I; Nakamura T; Ishikawa S; Saito T; Ishibashi S
Diabet Med; 2002 Apr; 19(4):347-8. PubMed ID: 11943013
[No Abstract] [Full Text] [Related]
7. Lack of effect of pioglitazone on postprandial triglyceride levels in type 2 diabetes.
Shimono D; Kuwamura N; Nakamura Y; Koshiyama H
Diabetes Care; 2001 May; 24(5):971. PubMed ID: 11347775
[No Abstract] [Full Text] [Related]
8. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients.
Jun JK; Gong WC; Mathur R
Am J Health Syst Pharm; 2003 Mar; 60(5):469-73. PubMed ID: 12635453
[No Abstract] [Full Text] [Related]
9. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
Dailey GE; Mohideen P; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
[TBL] [Abstract][Full Text] [Related]
10. Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.
Vergès B
Fundam Clin Pharmacol; 2007 Nov; 21 Suppl 2():15-8. PubMed ID: 18001314
[TBL] [Abstract][Full Text] [Related]
11. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.
LaCivita KA; Villarreal G
Curr Med Res Opin; 2002; 18(6):363-70. PubMed ID: 12442884
[TBL] [Abstract][Full Text] [Related]
12. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
King AB
Diabetes Care; 2000 Apr; 23(4):557. PubMed ID: 10857952
[No Abstract] [Full Text] [Related]
13. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
Mori Y; Itoh Y; Obata T; Tajima N
Endocrine; 2006 Feb; 29(1):143-8. PubMed ID: 16622303
[TBL] [Abstract][Full Text] [Related]
14. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
Pavo I; Jermendy G; Varkonyi TT; Kerenyi Z; Gyimesi A; Shoustov S; Shestakova M; Herz M; Johns D; Schluchter BJ; Festa A; Tan MH
J Clin Endocrinol Metab; 2003 Apr; 88(4):1637-45. PubMed ID: 12679450
[TBL] [Abstract][Full Text] [Related]
15. Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies.
Khan M; Xu Y; Edwards G; Urquhart R; Mariz S
Int J Clin Pract; 2004 Oct; 58(10):907-12. PubMed ID: 15587767
[TBL] [Abstract][Full Text] [Related]
16. [Thiazolidinediones: effect of the pioglitazone on hyperglycemia, dyslipidemia and cardiovascular risk].
Tan MH
Rev Clin Esp; 2003 Jan; 203(1):33-40. PubMed ID: 12605799
[No Abstract] [Full Text] [Related]
17. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients.
Nakamura T; Ushiyama C; Shimada N; Hayashi K; Ebihara I; Koide H
J Diabetes Complications; 2000; 14(5):250-4. PubMed ID: 11113686
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
[TBL] [Abstract][Full Text] [Related]
20. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]